非酒精性脂肪性肝病的诊断与治疗策略
Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease.
作者信息
Fu Yajie, Zhou Yanzhi, Shen Linhu, Li Xuewen, Zhang Haorui, Cui Yeqi, Zhang Ke, Li Weiguo, Chen Wei-Dong, Zhao Shizhen, Li Yunfu, Ye Wenling
机构信息
Key Laboratory of Receptors-Mediated Gene Regulation, Hebi Key Laboratory of Liver Disease, School of Basic Medical Sciences, The People's Hospital of Hebi, Henan University, Kaifeng, China.
Key Laboratory of Receptors-Mediated Gene Regulation and Drug Discovery, School of Basic Medical Science, Inner Mongolia Medical University, Hohhot, China.
出版信息
Front Pharmacol. 2022 Nov 2;13:973366. doi: 10.3389/fphar.2022.973366. eCollection 2022.
The global incidence rate of non-alcoholic fatty liver disease (NAFLD) is approximately 25%. With the global increase in obesity and its associated metabolic syndromes, NAFLD has become an important cause of chronic liver disease in many countries. Despite recent advances in pathogenesis, diagnosis, and therapeutics, there are still challenges in its treatment. In this review, we briefly describe diagnostic methods, therapeutic targets, and drugs related to NAFLD. In particular, we focus on evaluating carbohydrate and lipid metabolism, lipotoxicity, cell death, inflammation, and fibrosis as potential therapeutic targets for NAFLD. We also summarized the clinical research progress in terms of drug development and combination therapy, thereby providing references for NAFLD drug development.
非酒精性脂肪性肝病（NAFLD）的全球发病率约为25%。随着全球肥胖及其相关代谢综合征的增加，NAFLD已成为许多国家慢性肝病的重要原因。尽管在发病机制、诊断和治疗方面取得了最新进展，但其治疗仍面临挑战。在本综述中，我们简要描述了与NAFLD相关的诊断方法、治疗靶点和药物。特别是，我们专注于评估碳水化合物和脂质代谢、脂毒性、细胞死亡、炎症和纤维化作为NAFLD的潜在治疗靶点。我们还总结了药物开发和联合治疗方面的临床研究进展，从而为NAFLD药物开发提供参考。
Zotero 插件